Dysferlinopathy Gene Therapy

About Kinea Bio

Kinea Bio is a private, pre-clinical-stage biotech developing innovative gene therapy platforms and programs for neuromuscular diseases (NMDs) with high unmet need. The company has built a multi-faceted technology suite, including SIMPLI-GT™ for large gene delivery, MyoXpress™ for tuned muscle expression, myotropic capsids for targeted delivery, and BioDrone™ for non-immunogenic repeat administration. Backed by respected scientific founders, non-dilutive NIH grants, and foundation investments, Kinea is advancing a pipeline led by programs for Duchenne Muscular Dystrophy (DMD) and dysferlinopathy.

Therapeutic Areas